Currently Enrolling Studies

Participating in research studies at Howard Brown Health helps advance medical knowledge in hopes to improve care for LGBTQ patients, individuals living with HIV, and the broader population.

You do not need to be a Howard Brown patient to participate in our research studies but we will give you the option to link to care at Howard Brown.

Every research study is different. Before enrolling in a study at Howard Brown Health, a member of the research team will walk you through the process and the details of a study to make sure you’re eligible, aware of any risks and/or benefits to participating, and that it’s the right fit.

Some studies may include compensation for your time and effort. We will give you all the information and time you need to decide whether to participate.

Clinical Research

MERCK: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men.

For more information visit or contact a study coordinator at

MERCK: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL

For more information visit or contact a study coordinator at

RADx: COVID-19 Diagnostics Research

RADx is examining a variety of new types of tests that are being developed to find out which tests are accurate, quick, and easy to use. We believe the safety of people who take part in our research is the most important thing.
For more information, visit

Social Behavioral Research

Network Epidemiology of Syphilis Transmission (NEST)

This study intends to understand the interactions within MSM sexual and social networks to create better public health initiatives to reduce the transmission of Syphilis and other STIs. Study participant will complete surveys and STI screening every 3 months for 2 years.
To participate in the NEST Study, you must meet all of the below criteria:

For more information, email

Positive Steps

This study intends to test the effectiveness of multiple interventions in addressing challenges around anti-retroviral treatment adherence for people living with HIV.
To participate in the Positive Steps Study, you must meet all of the below criteria:

For more information, email

Community Network Driven COVID-19 Testing Among Most Vulnerable Populations in the Central United States (C3)

This study intends to learn more about how the COVID-19 pandemic is impacting the Latinx community, as well as share information and resources for COVID-19 testing with you and the people you spend time with on a regular basis (friends, family, co-workers, etc.). The purpose of this study is help prevent the spread of COVID-19 in Latinx communities by giving accurate information about COVID19 and linking participants to COVID-19 testing.
To participate in the C3 study, you must meet all of the below criteria:

For more information: Email

Using Telehealth to Address Alcohol Misuse in HIV Care (Reach3)

The studies primary aim is to test the hypothesis that telehealth counseling compared to brief intervention will result in reduced number of drinks consumed per week and number of heavy drinking days and increased odds of having an undetectable VL at 12- and 24-month follow-ups. View recruitment flyer.
To participate in the Reach3 study, you must meet all of the below criteria:

Click here to see if you are eligible by completing a brief screener:
For more information: Email or contact Ayla, Project Coordinator from Brown University, at 401.863.6858

If you are interested in volunteering for a current study through a research partner, please check our Collaborative Partners Studies for opportunities.


  • This field is for validation purposes and should be left unchanged.
This site is not optimized for Internet Explorer. Please consider viewing the site in a modern browser such as Edge, Chrome or Firefox.